Education and Training Postdoctoral Fellow, Massachusetts Institute of Technology, 2013 - 2016 Ph.D., University of Illinois at Urbana-Champaign, 2007 - 2012 B.S., Peking University, 2003-2007
Awards:
1999 Young Investigator Award Plenary Lectureship
, International Society for Neurochemistry
2011 Fellow
, ESMRMB
2011 Teaching Award
, Section Sciences de la Vie, EPFL
Dr. Michel Aguet, MD, held positions in academia and industry (Associate Professor at the Institute of Molecular Biology, University of Zürich; Head of Molecular Oncology, Genentech, So. San Francisco) before he was appointed director of the Swiss Institute for Experimental Cancer Research (ISREC) (1996-2009). In the context of the integration of ISREC into the Swiss Federal Institute of Technology (EPFL), he was appointed as Full Professor at the newly established School of Life Sciences in 2005. From 2001-2013 he directed the National Center of Competence in Research (NCCR) in Molecular Oncology, a national program launched by the Swiss National Science Foundation to encourage translational cancer research and for which ISREC was the leading house. Dr. Aguet has been a SAB member in the pharmaceutical industry, biotech industry and venture capital industry since 1997.
A large part of his scientific career was devoted to exploring the molecular biology of interferons (cloning of the interferon gamma receptor, generation of various interferon signaling mutants in the mouse) and, in collaboration with Prof. Charles Weissmann, to investigating the role of prion related protein PrP in mouse prion disease models. In recent years his research focused on characterizing the role of BCL9 proteins, which are part of the Wnt/beta-catenin transcriptional activation complex, in regulating stem cell traits in intestinal epithelium and colorectal cancer. His laboratory is now closed due to retirement.
Prof. Daniel Thalmann is Honorary Professor at EPFL and Director of Research development at MIRALab Sarl. He has been Visiting Professor at The Institute for Media Innovation (Nanyang Technological University, Singapore) from 2009 to 2017. He is a pioneer in research on Virtual Humans. His current research interests include Real-time Virtual Humans in Virtual Reality, crowd simulation, and 3D Interaction. Daniel Thalmann has been the Founder of The Virtual Reality Lab (VRlab) at EPFL, Switzerland, Professor at The University of Montreal and Visiting Professor/ Researcher at CERN, University of Nebraska, University of Tokyo, and National University of Singapore. Until October 2010, he was the President of the Swiss Association of Research in Information Technology and one Director of the European Research Consortium in Informatics and Mathematics (ERCIM). He is coeditor-in-chief of the Journal of Computer Animation and Virtual Worlds, and member of the editorial board of 6 other journals. Daniel Thalmann was member of numerous Program Committees, Program Chair and CoChair of several conferences including IEEE VR, ACM VRST, and ACM VRCAI. Daniel Thalmann has published more than 500 papers in Graphics, Animation, and Virtual Reality. He is coeditor of 30 books, and coauthor of several books including 'Crowd Simulation' (second edition 2012) and 'Stepping Into Virtual Reality' (2007), published by Springer. He received his PhD in Computer Science in 1977 from the University of Geneva and an Honorary Doctorate (Honoris Causa) from University Paul- Sabatier in Toulouse, France, in 2003. He also received the Eurographics Distinguished Career Award in 2010 and the 2012 Canadian Human Computer Communications Society Achievement Award. Wikipedia: http://en.wikipedia.org/wiki/Daniel_Thalmann Cathrin Brisken, MD, PhD, is Associate Professor of Life Sciences at the Swiss Federal Institute of Technology Lausanne (EPFL). Dr. Brisken is internationally recognized for her work on endocrine control of mammary gland development and breast carcinogenesis.
Dr. Brisken received her MD and her PhD degree in Biophysics from the Georg August University of Göttingen, Germany. She completed her postdoctoral work in cancer biology with Dr. R.A. Weinberg at the Whitehead Institute of Biomedical Research in Cambridge, MA, USA. She previously held appointments at the Cancer Center of the Massachusetts General Hospital, Harvard Medical School, Boston and the Swiss Institute for Experimental Cancer Research (ISREC).
Research in Dr. Brisken’s laboratory focuses on the cellular and molecular underpinnings of estrogen and progesterone receptor signaling in the breast and the respective roles of these hormones and hormonally active compounds in carcinogenesis. The aim is to understand how recurrent exposures to endogenous and exogenous hormones contribute to breast carcinogenesis in order to better prevent and treat the disease. The laboratory has pioneered in vivo approaches to genetically dissect the role of the reproductive hormones in driving mouse mammary gland development and shown how they control intercellular communication. Dr. Brisken’s group has developed ex vivo and humanized mouse models using patient samples to study hormone action in human tissues in normal settings and during disease progression.
Dr. Brisken is member of the International Breast Cancer Study Group (IBCSG) Biological Protocol Working Group. She served as Dean of EPFL Doctoral School (more than 2000 PhD students in 18 PhD programs), as member of the Hinterzartener Kreis, the oncology think-tank associated with the German Science Foundation, and numerous Swiss, European, and AACR committees. She co-founded the International Cancer Prevention Institute.
